{"id":"W2492626689","doi":"10.1007/s10637-016-0377-0","title":"A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":80,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; GlaxoSmithKline","keywords":"Dosing; Tolerability; Trametinib; Medicine; Adverse effect; Rash; MEK inhibitor; Pharmacokinetics; Cohort; Internal medicine; Pharmacology; Oncology; Gastroenterology; MAPK/ERK pathway; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001357325,0.001606287,0.002601137,0.0007665353,0.0005286481,0.001295579,0.0009476141,0.001320461,0.003977425],"category_scores_gemma":[0.000976295,0.000873111,0.00204882,0.0007324419,0.001095778,0.001371851,0.0004471965,0.00499915,0.001084932],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001370496,"about_ca_system_score_gemma":0.001810671,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001680522,"about_ca_topic_score_gemma":0.005255118,"domain_scores_codex":[0.9995942,0.0001439996,0.00002160986,0.00008498311,0.00003705884,0.0001182939],"domain_scores_gemma":[0.9993716,0.00008363322,0.0000885579,0.00006931236,0.00003788027,0.0003490289],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7061063,0.0927025,0.006662945,0.0008648147,0.002071219,0.0003145408,0.0004415934,0.006387265,0.03393732,0.000530385,0.005627205,0.144354],"study_design_scores_gemma":[0.6028264,0.3774505,0.01124383,0.00003740057,0.0005957182,0.0003036552,0.0001015789,0.001825808,0.002535819,0.0003421995,0.002689239,0.0000478612],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918542,0.001753501,0.0004520573,0.0007018751,0.0002157265,0.001838694,0.0009872726,0.0001215729,0.002075067],"genre_scores_gemma":[0.98964,0.001894517,0.001457589,0.000772963,0.0001414385,0.001544899,0.001855145,0.00004158764,0.002651932],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003977425,"threshold_uncertainty_score":0.01330578,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007907842871237351,"score_gpt":0.248194676809058,"score_spread":0.2402868339378207,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}